PCI 29732 inhibits the function of ABCG2 by competitively binding to the ATP-binding site of ABCG2 and enhances the anti-tumor efficacy of substrate chemotherapeutic agents[2].
PCI 29732 (20 mg/kg; p.o.; every 3 d × 5 times) enhances the anticancer efficacy of Topotecan in the H460/MX20 cell xenograft nude mice model[2].
| Animal Model: | 5-6 weeks old athymic nude mice (bearing H460/MX20 cells)[2] |
| Dosage: | 20 mg/kg (combination with Topotecan; every 3 d × 5 times, i.p., 3 mg/kg; topotecan was given 1 h after PCI29732 administration) |
| Administration: | P.o.; every 3 d × 5 times |
| Result: | Significant reductions in tumor weight and volume were observed in the group treated with PCI29732 in combination with Topotecan.
|